Search

Showing 1 - 10 of 532 results.

Guidelines

Summary of current relevant international guidelines on the diagnosis of TR Transcatheter tricuspid valve intervention has now been elevated to a Class IIa, Level of Evidence (LoE) A recommendation
Amplatzer Piccolo™ Occluder

SWITCH TO THE REFERRAL VIEW For more information specific to neonatology regarding PDA closure AMPLATZER PICCOLO™ OCCLUDER: FOR PDA CLOSURE IN THE SMALLEST PATIENTS INDUSTRY-LEADING
Connext

Therapies Valvular Diseases Mitral Valve Disease Aortic Valve Disease Tricuspid Valvle Disease Paravalvular Leak
Overview

*For 27 mm valve size, measured from the farthest point of the cuff. *There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in hum
Overview

LEARN MORE: DIAGNOSIS TREATMENT AS is a progressive disease. While patients with AS may initially be asymptomatic, further progression is typically associated with symptoms and poor pro
Diagnosis

The three cardinal symptoms of AS are angina, syncope or heart failure (HF).13,16 Other symptoms include dyspnea and decreased exercise tolerance.14 Primary care physicians should consider AS in ad
Options

Treatment options for aortic stenosis: MEDICAL MANAGEMENT Medical treatment options for symptomatic patients with severe AS are limited. Medical treatment may be helpful in ameliorating symptoms in
Surgical Replacement

LEARN MORE: Tissue Heart Valves Mechanical Heart Valves
Guidelines

Asymptomatic patients Intervention is recommended in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <50%) without another cause (class I, B). Interventi
Options

As recommended in the 2020 American College of Cardiology/American Heart Association (ACC/AHA) and 2021 ESC/EACTS guidelines,38,39 patients with TR should be managed by a multidisciplinary heart tea